Abstract: Investigation of cannabinoid pharmacology in a vertebrate with a phylogenetic history distinct from that of mammals may allow better understanding of the physiological significance of cannabinoid neurochemistry. Taricha granulosa, the roughskin newt, was used here to characterize an amphibian cannabinoid receptor. Behavioral experiments demonstrated that the cannabinoid agonist levonantradol inhibits both newt spontaneous locomotor activity and courtship clasping behavior. Inhibition of clasping was dose-dependent and potent (IC 50 ϭ 1.2 g per animal). Radioligand binding studies using [ 3 H]CP-55940 allowed identification of a specific binding site (K D ϭ 6.5 nM, B max ϭ 1,853 fmol/mg of protein) in brain membranes. Rank order of affinity of several ligands was consistent with that reported for mammalian species (K D , nM): CP-55940 (3.8) Ͼ levonantradol (13.0) Ͼ WIN55212-2 (25.7) Ͼ Ͼ anandamide (1,665) Ϸ anandamide ϩ 100 M phenylmethylsulfonyl fluoride (2,398). The cDNA encoding the newt CB1 cannabinoid receptor was cloned, and the corresponding mRNA of 5.9 kb was found to be highly expressed in brain. A nonclonal Chinese hamster ovary cell line stably expressing the newt CB1 cannabinoid receptor was prepared that allowed demonstration of cannabinoid-mediated inhibition of adenylate cyclase (EC 4.6.1.1) activity. This inhibition was dose-dependent and occurred at concentrations consistent with affinities determined through radioligand binding experiments. The behavioral, pharmacological, and molecular cloning results demonstrate that a CB1 cannabinoid receptor is expressed in the CNS of the roughskin newt. This amphibian CB1 is very similar in density, ligand binding affinity, ligand binding specificity, and amino acid sequence to mammalian CB1. The high degree of evolutionary conservation of cannabinoid signaling systems implies an important physiological role in vertebrate brain function. Key Words: CannabinoidAmphibian-G protein-coupled receptor-Adenylate cyclase -Locomotor behavior-Sex behavior. J. Neurochem. 75, 413-423 (2000).
The active constituents of Cannabis sativa have been used for centuries for their medicinal and psychoactive properties. Despite this long history of cannabinoid use an understanding of cannabinoid pharmacology has only recently begun to emerge.
This progress was initiated with evidence that cannabinoids inhibit neuronal adenylate cyclase activity through activation of G proteins (Howlett and Fleming, 1984; Howlett, 1985) . Cannabinoid activation of G proteins with an appropriate pharmacological signature implied the presence of specific cannabinoid receptors. Two subtypes of specific cannabinoid receptors have been identified: CB1, CNS-associated [although peripheral expression has been detected (Devane et al., 1988; Matsuda et al., 1990)] , and CB2, which may be exclusively expressed within tissues of the immune system (Munro et al., 1993) .
Both cannabinoid receptor subtypes alter cellular activity through activation of G proteins of the G i/o subtype, although reports suggest that G s activation also occurs (Howlett, 1985; Bayewitch et al., 1995; Glass and Felder, 1997) . Activation of G i/o by CB1 and CB2 receptors effects decreases in adenylate cyclase activity, which leads to decreased levels of intracellular cyclic AMP (cAMP). G protein activation by both cannabinoid receptor subtypes has been implicated in modulating the mitogen-activated protein kinase signaling pathway and Krox-24 (zenk) induction (Bouaboula et al., , 1996 . CB1 but not CB2 activation has been shown to be negatively coupled through G i/o to N-type and P/Q-type calcium channels and positively coupled to inward-rectifying potassium channels (Mackie and Hille, 1992; Mackie et al., 1995) .
Progress in cannabinoid research has been helped by development of various synthetic cannabinoid ligands of different structural classes. These include compounds with structural similarity to the principal psychoactive constituent of marijuana, ⌬ 9 -tetrahydrocannabinol, e.g., levonantradol and CP-55940, aminoalkylindole cannabinoids, e.g., WIN55212-2, and an endogenous fatty acid ligand, arachidonyl ethanolamide or anandamide (Devane et al., 1992b) . Several additional fatty acid compounds capable of activating cannabinoid receptors have been isolated or synthesized. Among these are mead ethanolamide (Priller et al., 1995) , arachidonyl glycerol , and conjugated triene anandamide (Wise et al., 1996) . The array of cannabinoid ligands also now includes CB1-and CB2-selective antagonists: SR-141716A for CB1 (Rinaldi-Carmona et al., 1994) and SR-144528 for CB2 (Rinaldi-Carmona et al., 1998) .
Preliminary evidence has been obtained for cannabinoid signaling in nonmammalian species, including zebra finch (Soderstrom and Johnson, 2000) , pufferfish (Yamaguchi et al., 1996) , leech (Stefano et al., 1997) , mussel (Stefano et al., 1998) , and Hydra (De Petrocellis et al., 1999) . In each of these cases a thorough characterization has yet to be completed. It is interesting that the translation of cDNA fragments possibly encoding a leech CB1 reveals homology with melanocortin receptors, implying a possible ancestral relationship (Elphick, 1998) .
Despite progress over the last decade, a clear physiological role for the systems regulated by cannabinoid receptor activation has not emerged. High levels of CB1 expression [Ͼ2,000 fmol/mg of protein in rat whole brain membranes (Pertwee, 1997) ] imply functional importance. The nature of the(se) important physiological role(s) mediated by cannabinoid signaling systems is presently unclear. Better understanding of cannabinoid activity is dependent on development of model systems that will allow investigation of specific aspects of cannabinoid effects. As most research investigating cannabinoid pharmacology has been done with mammals, there is a need for comparative studies of cannabinoid systems in other species. Comparative studies should allow identification of cross-species similarities and differences that will provide insight to the functional role of cannabinoid signaling and how this role may have developed and changed over the course of evolution. The thorough characterization of a newt CB1 cannabinoid receptor (nCB1R) presented here represents progress toward developing such a system in an amphibian.
MATERIALS AND METHODS

Materials
Except where indicated, reagents were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.) or Fisher (Pittsburgh, PA, U.S.A.). Levonantradol and CP-55940 were gifts from Pfizer (Groton, CT, U.S.A.). Ro 20-1724, WIN55212-2, and anandamide were purchased from RBI (Natick, MA, U.S.A. A.) . GF/C filters were purchased from Brandel (Gaithersburg, MD, U.S.A.). Enzymes and reagents used for cDNA synthesis reactions were purchased as a kit (TimeSaver cDNA Synthesis Kit) from Pharmacia (Piscataway, NJ, U.S.A.). Enzymes and reagents used for construction of cDNA libraries in ZAPII and gt11 were purchased from Stratagene (San Diego, CA, U.S.A.). Oligonucleotide primers, cell culture media, Moloney murine leukemia virus reverse transcriptase, and other reagents for RT-PCR were purchased from Life Technologies (Grand Island, NY, U.S.A.). Fetal bovine serum was purchased from Summit (Denver, CO, U.S.A.). Brightstar nitrocellulose blotting membranes were purchased from Ambion (Austin, TX, U.S.A.). Nitrocellulose disks for plaque lift screening were purchased from Schleicher & Schuell (Keene, NH, U.S.A.).
Spontaneous locomotor behavior
Male roughskin newts (Taricha granulosa) were collected from ponds in Benton County, OR, U.S.A. These animals were transported to a laboratory where they were maintained in large fiberglass tanks containing dechlorinated water at 17°C. After locomotor behavior experiments, animals were returned to the ponds from which they were captured.
Animals were randomly assigned to treatment and vehicle control groups. Injections of 100 l were made into the peritoneal cavity. Levonantradol was suspended at various concentrations into a vehicle of 1% ethanol in water.
At 30 min postinjection animals were placed into 15-L tanks (diameter ϭ 40 cm) filled to a depth of ϳ15 cm with water at 17°C. Dark lines drawn on the bottom of the testing tank created eight sectors of equal area in a radial pattern. The center of each tank was obstructed with a large Styrofoam cup. Animals were scored for locomotor behavior according to the number of times their heads crossed a sector line. Counting began 1 min after animals were placed into the testing bucket and continued for a total of 3 min. The observer in these experiments was blind to treatment. Significance of results was assessed by Student's t test.
Courtship clasping behavior
During mating season (January-March), roughskin newts display a characteristic courtship clasping behavior. Male newts initiate this behavior by first capturing a female in an amplectic clasp and then holding her firmly with all four limbs. This clasping position is easily identified and measured and is maintained for long periods, often hours. Cannabinoid effects on this male clasping behavior were measured in the field at a lake in the coastal mountains near Benton County, OR.
Female roughskin newts were captured before each experiment and transported to a laboratory where they were maintained in large fiberglass tanks containing dechlorinated water at 17°C. These females were injected with 100 g of progesterone the day before clasping behavior experiments and transported back to the field for use as clasping targets.
The day of experiments, male newts were collected from the lake constituting the experiment site and randomly assigned to treatment groups. These male newts were then placed in tanks prepared with perforations that allowed free circulation of pond water. The perforated tanks were then suspended from a raft floating in the lake.
All treatments were administered by intraperitoneal injection of 100 l. After a 1-h equilibration period following capture and assignment to treatment groups, males were treated with levonantradol or a vehicle control. At 15 min after treatment, female newts were introduced into testing tanks, and observation and recording of clasping behavior commenced. Numbers of males clasping and the latency to clasp were recorded.
Statistics
Locomotor activity scores (described above) were analyzed with Student's t test (two-tailed). In an initial two-sample clasping behavior experiment animals were treated with 5 g of levonantradol or vehicle (n ϭ 25 animals each) and scored for clasping behavior and the latency of response (see Fig. 1 ). Cumulative numbers of claspers in 5-min intervals were analyzed using Fisher's exact probability test. This two-sample experiment was followed by a dose-response experiment in which groups of 12 animals each received 0.1, 0.32, 1, 3.2, or 5.6 g of levonantradol. The relationship between levonantradol dosage and the total numbers of claspers in each group was evaluated using a 2 analysis.
Preparation of newt neuronal membranes
Well-washed newt neuronal membranes were used in radioligand binding experiments designed to detect the presence of amphibian cannabinoid receptors. To prepare these membranes newt brains (taken from naive animals) were homogenized using a glass-Teflon homogenizer in 25 volumes (based on tissue weight) of cold 0.32 M sucrose containing 5 mM HEPES. This homogenate was then centrifuged at 1,000 g for 15 min at 4°C. The supernatant from this low-speed centrifugation was collected and centrifuged at 30,000 g for 30 min at 4°C. The pellet from this second centrifugation was snap-frozen at Ϫ70°C, thawed, resuspended using a glass-Teflon homogenizer in 150 volumes of 25 mM HEPES/10 mM EDTA buffer, and incubated for 30 min at 4°C. Membranes were pelleted at 30,000 g for 30 min at 4°C, followed by a second snap-freeze at Ϫ80°C. The resulting pellet was resuspended in 25 mM HEPES and pelleted at 30,000 g for 30 min at 4°C. This final pellet was resuspended in assay buffer (25 mM HEPES/10 mM MgCl 2 , pH 7.4) and stored frozen at Ϫ70°C until needed for binding assays.
Radioligand binding assays
To detect cannabinoid binding sites in newt neuronal membranes, the synthetic cannabinoid agonist CP-55940 in tritiated form (103 or 131 Ci/mmol) was used in the binding studies described. Binding reaction were conducted in a final volume of 500 l containing 25 mM HEPES, 10 mM MgCl 2 , 0.5% bovine serum albumin, 0.1% ethanol, and 60 -185 g of membrane protein. Nonspecific binding was defined as that occurring in the presence of 1 M levonantradol (diluted from a 10 mM stock). Equilibrium binding experiments were routinely conducted over 480 min and terminated by rapid filtration over GF/C glass fiber filters. Filters were washed immediately after termination of binding reactions with 6 ml of ice-cold assay buffer. Filter-trapped radioactivity was quantified by use of a Beckman model LS 6500SC scintillation counter.
Radioligand binding data were analyzed by computer-assisted nonlinear regression analysis using GraphPad (San Diego) Prism software. This program fits appropriate equations to data using iterative least-squares curve-fitting algorithms. The relative appropriateness of a one-binding-site model compared with a multiple-site model was evaluated through F tests that determine if additional parameters improve the fit of the data to the more complex equation. Inhibitory binding constant (K i ) values were calculated from IC 50 values using the ChengPrusoff equation (Cheng and Prusoff, 1973) .
Isolation of newt brain RNA and production of cDNA libraries
To study the molecular pharmacology of cannabinoid signaling in the newt, cDNA libraries were constructed so that the nCB1R could be cloned and functionally expressed. Male roughskin newts that were naive to cannabinoid treatment were rapidly decapitated, and brains were quickly dissected and immediately frozen in liquid nitrogen. The nitrogen was evaporated, and the frozen tissue (ϳ500 mg) was quickly homogenized with a Polytron in 25 ml of a chaotropic buffer consisting of 4 M guanidium isothiocyanate, 20 mM sodium acetate, 0.1 mM dithiothreitol, and 0.5% Sarkosyl. The homogenate was layered over 5.7 M CsCl and centrifuged for 20 h at 150,000 g at 18°C. The resulting total RNA pellet was resuspended in 500 l of RNase-free water. The average yield of total RNA from 500 mg of tissue was 700 g. Polyadenylated RNA was isolated from total RNA using oligo(dT)-Sepharose columns (Pharmacia; catalogue no. 27-9258-01). Polyadenylated RNA used for cDNA library construction was purified twice over oligo(dT)-cellulose columns. The average yield of polyadenylated RNA from 700 g of total RNA was 15 g. Newt brain cDNA was synthesized from ϳ5 g of polyadenylated RNA using random and oligo(dT) 12-18 primers and a cDNA synthesis kit (Pharmacia; catalogue no. XY-033-00-07). The cDNA (ϳ100 ng) was ligated to ZAPII or gt11 phage arms (Stratagene). The resulting recombinant phage DNA was packaged using commercially available extracts (Stratagene).
PCR using degenerate primers
Degenerate primer PCR was used to produce an nCB1R-specific probe for northern blotting and cDNA library screening. Human, rat, mouse, and pufferfish CB1 amino acid sequences were aligned, highly conserved regions encoding portions of the second and seventh transmembrane spanning domains of the CB1 receptors of these species were selected, and degenerate primers for use in PCR amplification were deduced.
A 5Ј sense primer was synthesized, corresponding to the human CB1 receptor amino acids 153-157 (H 2 N-YHFIG-COOH). Addition of a spacer and HindIII restriction site resulted in the following primer: 5Ј-ATG AAG CTT TAC CAC TTC AT(C/T/A) GG-3Ј.
A 3Ј antisense primer was designed based on human CB1 receptor amino acids 381-386 (FCSMLC). Taking the complement of oligonucleotides encoding these residues and adding a 5Ј spacer and XbaI restriction site resulted in the following degenerate primer: 5Ј-CAT TCT AGA GCA CAG CAT (A/ G)CT (G/A)CA (G/A)AA-3Ј.
Degenerate primers were used for 40 cycles of Taq polymerase-catalyzed PCR using the following temperature steps and times: denaturation at 94°C for 30 s, annealing at 40 -48°C for 60 s, and extension at 72°C for 90 s. The cDNA used to construct newt brain cDNA libraries was used as a template. Annealing temperatures of 40°C were used for the first five cycles, followed by 48°C for the remaining 35. The 715-bp product of this reaction was subcloned and sequenced.
Northern blot analysis
To determine the size of the mRNA encoding the nCB1R, total RNA from various newt tissues including lung, heart, testes, digestive tract, skeletal muscle, liver, and spleen was isolated as described above for brain. These RNAs (25 g each) were separated by electrophoresis through a formaldehyde-containing agarose gel and transferred to a nylon membrane. Blots were probed according to standard protocols using the nCB1R degenerate primer PCR product as a probe.
After a suitable film image had been obtained using the nCB1R probe, the membrane was stripped and probed again for 18S RNA as a loading control.
RT-PCR
To investigate possible expression of nCB1R in peripheral tissues at levels too low to detect with northern blotting, the more sensitive technique of RT-PCR was used: One microgram each of the total RNA isolated from various newt tissues was used to synthesize first-strand cDNA using Moloney murine leukemia virus reverse transcriptase and an oligo(dT) 12-18 primer. A 1-l aliquot of each of these cDNA synthesis reactions was used as a template for PCR using nCB1R-specific primers. The 5Ј and 3Ј primers used for these amplifications correspond to bases 1,012-1,030 and 1,401-1,422 of the nCB1R coding sequence, respectively. The amplification protocol consisted of 30 cycles of PCR using Taq polymerase and a "touchdown PCR" annealing temperature program. The initial annealing temperature was 60°C, which was decreased each cycle until 50°C was reached, after which remaining cycles were performed using a 50°C annealing temperature. Twenty-five percent of each PCR procedure was used for gel electrophoresis, and the relative intensities of bands were assessed after ethidium bromide staining and photography.
cDNA library screening
Newt brain cDNA libraries were screened using the nCB1R degenerate PCR fragment as a probe. Screening resulted in isolation of two clones, which together produced a cDNA encoding nCB1R. These clones were joined using a unique BstZ17I restriction site and ligated into pBluescript (Stratagene). This clone was used as a template for 20 cycles of Pfu-catalyzed PCR using primers designed to amplify the nCB1R coding sequence without untranslated regions. This PCR product was subcloned into the HindIII and XhoI sites of the pTL1 eukaryotic expression vector (Leid et al., 1992) , resulting in the plasmid pTL1nCB1R. The nucleic acid sequence encoding the nCB1R is available from GenBank (accession no. AF181894).
Chinese hamster ovary (CHO) cell transfections
CHO cell cultures were transfected with pTL1nCB1R and pRC/RSV(Ϫ) (Invitrogen; to impart neomycin resistance) using a standard calcium phosphate-based method. Two days after transfection confluent 100-mm-diameter dishes were split into four 150-mm-diameter plates and cultured in medium containing G418 (750 g/ml). Isolated, G418-resistant colonies became visible after 10 -14 days and were harvested without clonal selection in complete medium containing 10% dimethyl sulfoxide, and samples were stored in liquid nitrogen or further cultured for use in adenylate cyclase assays.
Adenylate cyclase assays
To investigate newt cannabinoid receptor signal transduction, adenylate cyclase assays were performed according to a modified version of the method of Salomon (1979) . The nCB1R-expressing CHO (CHO-nCB1) cell cultures were washed twice with serum-free F12 Hams's medium and then incubated for 4 h in 1 ml of the same medium containing 1.2 Ci of [ 3 H]adenine. The tritium-containing medium was then aspirated and replaced with serum-free F12 Ham's medium containing a phosphodiesterase inhibitor (50 M Ro 21-1724). These cultures were incubated at 37°C for 40 min in the presence of 25 M forskolin and various concentrations of cannabinoids. Incubations were terminated by addition of 300 l of stop solution (2% sodium dodecyl sulfate and 2.3 mM cAMP), followed by addition of 100 l of concentrated perchloric acid and 750 l of water. [
14 C]cAMP (5,000 cpm in 50 l) was added to each plate to correct for recovery. After transferring the contents of culture dishes to 1.5-ml centrifuge tubes, 12 M KOH was added to neutralize the samples. The resulting precipitate was pelleted by centrifuging at 10,000 g for 10 min. The cAMP in the supernatants was isolated by sequential chromatography over Bio-Rad AG 50W-X4 cation exchange resin and neutral alumina. 
Phylogenetic and sequence analysis
The phylogenetic relationships of CB1 cannabinoid receptors of known complete amino acid sequence were estimated in a three-step process: First, amino acid sequences were aligned using the ClustalW multiple alignment computer program (available on the EMBL web site). Second, genetic distances were estimated using the PROTDIST computer program, and finally a dendrogram was computed from genetic distance estimates using the FITCH computer program. The PROTDIST and FITCH programs are available as part of the PHYLIP set of phylogenetic analysis tools (Felsenstein, 1988) . The BOX-SHADE alignment graphics program (version 3.2, available from EMBL) was used to highlight sequence similarities from ClustalW output (see Fig. 6 ).
RESULTS
Cannabinoids inhibit male newt locomotor activity and courtship clasping behavior
Treatment of male newts with 5-g injections of the cannabinoid agonist levonantradol significantly inhibited spontaneous locomotor activity. A group of 50 vehicle control animals crossed an average of 11.4 Ϯ 1.5 lines during the 3-min testing period. The same number of animals treated with levonantradol crossed a significantly lower average of 4.1 Ϯ 0.9 lines ( p Ͻ 0.01 by two-tailed t test; data not shown).
Five-microgram injections of levonantradol also inhibited male newt courtship clasping behavior (Fig. 1) . Inhibition of clasping was significant 45 min after levonantradol injections had been administered ( p Ͻ 0.05 by Fisher's exact probability test). Levonantradol-mediated FIG. 1. Effects of levonantradol on incidence and latency to incidence of male clasping behavior in newts. The arrow indicates the time at which females were added to testing buckets. Data are presented as cumulative percentage of clasping males at 5-min intervals. Males injected with levonantradol were significantly inhibited within 40 min: *p Ͻ 0.05 by Fisher's exact probability test.
inhibition of clasping behavior was further investigated in a dose-response experiment. Six groups of 12 newts each were given injections containing 0.1, 0.32, 1, 3.2, or 5.6 g of levonantradol. Results demonstrate that levonantradol-mediated inhibition of clasping behavior is dose-dependent (with the incidence of behavior inversely proportional to the dose) and potent (EC 50 ϭ 1.2 g per animal; 95% confidence interval ϭ 1.0 -3.9 g per animal; data not shown; average newt weight ϭ 15 g). The 2 analysis indicated a significant relationship between levonantradol dosage and incidence of clasping behavior ( p Ͻ 0.05).
High-affinity [ 3 H]CP-55940 binding sites are present in newt neuronal membranes
Equilibrium saturation binding of [ 3 H]CP-55940 to newt neuronal membranes demonstrated a specific interaction that is saturable and of high affinity (Fig. 2) . Over the concentration range used, an apparently single population of sites was labeled as reflected in a linear Scatchard replot of the data (Fig. 2, inset ). Labeling occurred with high affinity (K D ϭ 6.5 Ϯ 1.3 nM), and the density of binding sites in these membranes is high (B max ϭ 1,853 Ϯ 161 fmol/mg of protein). At a concentration of radioligand approximating the K D , ϳ50% of total binding was specific.
Kinetic analysis of the binding of [ 3 H]CP-55940 to Taricha neuronal membranes revealed that equilibrium binding was reached by 480 min at 15°C (Fig. 3) . Association and dissociation of [ 3 H]CP-55940 to the binding site were monophasic. The k Ϫ1 estimated from the fit of the dissociation data was 6.84 ϫ 10 Ϫ3 Ϯ 7.91 ϫ 10 Ϫ4 min Ϫ1 . The k obs determined from the association data was 7.07 ϫ 10 Ϫ3 Ϯ 7.71 ϫ 10 Ϫ4 min Ϫ1 . With a radioligand concentration of 0.094 nM, these parameters resulted in a kinetically derived K D ϭ 2.7 nM, a value in reasonable agreement with that obtained through equilibrium saturation binding experiments. The agreement of affinity values obtained through equilibrium saturation binding and kinetic studies supports the validity of the methods used for these binding experiments.
The specificity of the cannabinoid binding site in newt neuronal membranes was evaluated through a series of equilibrium competition binding experiments. These experiments used several cannabinoids with diverse structures. The cannabinoids displaced [ 3 H]CP-55940 from an apparently single binding site with a distinct rank order of affinity, establishing a pharmacological profile for this amphibian cannabinoid receptor (K D , nM): CP-55940 (3.8) Ͼ levonantradol (13.0) Ͼ WIN55212-2 (25.7) Ͼ Ͼ anandamide (1665) Ϸ anandamide ϩ 100 M phenylmethylsulfonyl fluoride (2,398). Results of equilibrium saturation binding experiments are summarized in Table 1 .
The nCB1R is expressed at high levels in brain
Results of northern blot analysis of total RNA isolated from various newt tissues are presented in Fig. 4 . These results indicate that the cannabinoid nCB1R is expressed in brain at higher levels than in lung, heart, testes, digestive tract, skeletal muscle, liver, or spleen (Fig. 4A ). Based on a standard curve calculated from the migration 
FIG. 3. Kinetics of specific [
3 H]CP-55940 (94 pM) binding to newt neuronal membranes (50 g) at 15°C. A: Association proceeded for the times indicated. Data were best fit by an equation describing a one-site association with k obs ϭ 7.07 ϫ 10 3 /min. B: Dissociation after incubation with radioligand for 480 min before addition of 100 M levonantradol. Data were best described using a one-site model with k Ϫ1 ϭ 6.84 ϫ 10 Ϫ3 /min. of RNA molecular weight standards, the size of the nCB1R transcript is estimated to be 5.9 kb.
To evaluate potential nCB1R expression in peripheral tissues, RT-PCR experiments were performed (see Fig.  4C ). These results suggest that, in addition to brain, the nCB1R may be expressed at significant levels in newt digestive tract.
The nCB1R heterologously expressed in CHO cells is negatively coupled to adenylate cyclase
Functional expression of the newt cannabinoid receptor was detected through adenylate cyclase assays performed using a nonclonal CHO cell line stably expressing the nCB1R (CHO-nCB1 cells). Results of these experiments are presented in Fig. 5 . Treatment of CHOnCB1 cells with levonantradol resulted in a modest inhibition of forskolin-stimulated (25 M) adenylate cyclase activity (21.5%). Inhibition was not observed in untransfected CHO cell cultures treated with 1 M levonantradol.
DISCUSSION
The results presented herein represent a behavioral, pharmacological, and molecular characterization of a CB1 cannabinoid receptor from a lower vertebrate species. Prior characterization of CNS cannabinoid receptors has been primarily restricted to mammalian species.
The inhibition of newt spontaneous locomotor behavior by levonantradol is consistent with cannabinoid agonist production of hypomobility in mammalian species (Martin et al., 1991; Wiley et al., 1995) . Inhibition of newt clasping is consistent with reports of increased latency to first mount and latency to ejaculation in rats treated with ⌬ 9 -tetrahydrocannabinol (Merari et al., 1973) . Inhibition of newt courtship clasping (consistent with that produced by cannabinoids) has also been observed after treatment with corticosterone (Moore and Miller, 1984) . This corticosterone-mediated inhibition of clasping behavior is associated with activation of a steroid receptor within newt neuronal membranes (Orchinik et al., 1991) . The specificity of levonantradol inhibition of newt clasping behavior is supported by both the potent and dose-dependent manner in which the effect was produced. Despite this potency and dose dependence, it is impossible to rule out a possible contribution of levonantradol-mediated inhibition of locomotor activity. Even at the highest levonantradol dosage level, no incidence of catalepsy or immobility was observed.
The saturation and kinetic binding experiments presented demonstrate that an apparently single high-affinity cannabinoid binding site is present within newt neuronal membranes. The equilibrium competition experiments demonstrate the pharmacologic specificity of this binding site. The specificity of the binding site for vari- PMSF, phenylmethylsulfonyl fluoride.
FIG. 4. Expression of the nCB1R gene in various tissues. A:
Northern blot probed with nCB1R. Numbers on the left indicate migration of RNA molecular weight standards. Bands corresponding to nCB1R transcripts are estimated to be 5.9 kb and are only visible in brain samples. B: The same blot reprobed with an 18S rRNA probe. Similar intensities of 18S rRNA bands present in all tissues except brain mRNA demonstrate that similar amounts of total RNA (25 g) were loaded across tissue types. C: RT-PCR analysis of nCB1R expression in various tissues. Thirty cycles of Taq-catalyzed PCR were done using annealing temperatures decreasing from 60 to 50°C. The 428-bp nCB1R fragments visible in the ethidium bromide-stained gel were amplified from brain and digestive tract RNA. A brain RNA control without reverse transcriptase is shown (No RT).
FIG. 5. Inhibition of forskolinstimulated [
3 H]adenine incorporation into cAMP. CHO-nCB1R cells were treated for 20 min with 25 M forskolin (100% of control) and the concentrations of levonantradol shown. Maximal inhibition was 21.5% with an IC 50 of 1.8 nM. Data points represent the means Ϯ ranges (bars) of two pooled experiments performed in triplicate.
ous cannabinoids is consistent with that observed using membranes derived from mammalian tissue and cell cultures heterologously expressing CB1 receptors (Pertwee, 1997). Taken together, these binding data are consistent with the expression of a CB1-like cannabinoid receptor in newt brain tissue that is very similar in pharmacology to mammalian homologues. The affinity of this newt brain cannabinoid receptor for [ 3 H]CP-55940 (6.5 nM) is somewhat lower than that reported for mammalian species, e.g., 0.13 nM in the rat (Devane et al., 1988) . This lower affinity may be attributable to a lower incubation temperature used for binding experiments with newt tissue (15 vs. 30°C for mammalian tissue). This lower incubation temperature was used to approximate conditions physiologically relevant to the newt.
The only notable inconsistency in the rank order of affinity of various cannabinoid ligands for newt neuronal membranes as compared with that of mammalian CB1 receptors involves the interaction of the endogenous cannabinoid anandamide. Anandamide effectively displaces [ 3 H]CP-55940 binding from both newt and mammalian neuronal membranes but interacts with newt neuronal membranes with a lower affinity [2,398 nM for newt vs. 52-266 nM for rat (Pertwee, 1997) ]. Again, this apparent lower affinity may be due to different incubation temperatures used in binding experiments. Modifying our binding reaction to 30°C for 90 min we have found that anandamide (with 100 M phenylmethylsulfonyl fluoride) will displace [ 3 H]CP-55940 from newt neuronal membranes with K i ϭ 418 nM (95% confidence interval ϭ 272-643 nM; data not shown), an affinity lower than what we found using rat membranes under the same conditions [97 nM (Wise et al., 1996) ].
The tissue distribution results obtained through northern blotting techniques clearly demonstrate that, of the tissues evaluated, highest expression of the nCB1R gene occurs in brain. It is possible that significant expression does occur in other tissues tested but at levels undetectable under the northern blotting conditions used. To evaluate this possibility, the more sensitive technique of RT-PCR was used. The results of RT-PCR experiments corroborate northern blotting results and, in addition, suggest that significant expression may occur in tissues of the digestive tract. Digestive tract expression of nCB1R is consistent with cannabinoid agonist inhibition of ileum contraction in tissues isolated from guinea pigs and humans . Before definite conclusions based on such RT-PCR experiments can be made, suitable controls for cDNA template amounts used for the PCR will have to be developed, and a more extensive set of newt-specific controls will have to be used. Such controls may allow for future quantitative evaluation of relative expression levels.
High-level nCB1R expression in brain is consistent with results obtained with mammalian species. Northern blots using RNA isolated from mammalian tissue have only detected CB1 receptor expression in CNS, testes (Gerard et al., 1991) , and uterus (Das et al., 1995) , and the signals obtained with these peripheral tissues were reported to be modest relative to those obtained with brain. Use of RT-PCR techniques has allowed detection of CB1 receptor expression in a wide array of mammalian tissues, including adrenal gland, heart, lung, prostate, uterus, ovary, testis, bone marrow, thymus, and tonsils (Galiegue et al., 1995) and colon, stomach, liver, pancreas, placenta, kidney, leukocytes, and vas deferens .
Cannabinoid agonist-mediated inhibition of adenylate cyclase in CHO cells stably expressing the newt cannabinoid receptor suggests functional coupling to G proteins of the G i/o subtype. Such G protein coupling is consistent with that reported from experiments using primary neuronal cell cultures and cell lines stably expressing mammalian CB1 receptors (Howlett et al., 1986) . The modest magnitude of inhibition (21.5%; Fig.  5 ) of forskolin-stimulated adenylate cyclase activity produced by cannabinoid agonists in our nCB1R-expressing cell line may be attributable to its nonclonal nature. This cell line may contain a significant number of clones either not expressing the receptor or expressing it at low levels. Non-or underexpressing cells are susceptible to forskolin stimulation without cannabinoid-mediated inhibition, thereby reducing the cAMP signal measured in the assay. The nCB1R-mediated cyclase inhibition occurred with an IC 50 ϭ 1.8 nM, which is somewhat lower than its affinity as determined in competition binding experiments with newt neuronal membranes (IC 50 ϭ 13.0 nM). Again, the difference between these values may be attributable to differences in the temperature used for cannabinoid treatment of CHO-nCB1 cells (37°C) and the low incubation temperatures (15°C) used in the binding experiments.
Notable features of the cDNA encoding nCB1R (GenBank accession no. AF181894) include bases 101-107, which are analogous to the splice donor site identified in the human CB1 receptor sequence and responsible for producing the splice variant CB1A. The splice donor site for human CB1A receptor is not present in the nCB1 receptor sequence. The deduced amino acid sequence of the nCB1R is presented in Fig. 6 and compared with those of all other CB1 receptors for which complete protein sequence information is available (although functional expression of the cat and pufferfish clones has not been reported, rendering their status as coding sequences questionable). In Fig. 6 , predicted transmembrane domains (TMDs) are numbered, and their locations are indicated by heavy lines. Intracellular domains are italicized, which distinguishes them from extracellular segments. Features that are highly conserved between the nCB1R and those cloned from other species receptors include the following: (a) Dual sites for N-linked glycosylation are present in the N-terminal extracellular domain (indicated in bold type). (b) Potential sites exist for protein kinase C (PKC) phosphorylation in the first (between TMDI and TMDII) and third (between TMDV and TMDVI) intracellular regions.
FIG. 6.
Amino acid alignment of CB1 cannabinoid receptors with complete predicted protein sequence. Putative transmembrane domains are numbered, and locations are indicated by heavy lines. Intracellular domains are distinguished from extracellular segments with italic type. Conserved amino acids are indicated by black letters against a white background, regions with similar amino acids are indicated in black letters against a shaded background, and regions of dissimilarity are in white letters against a black background. Tick marks above the first row and below the last row are placed after every 10th residue. Other notable regions and residues are indicated and described in the text. PFish, pufferfish.
PKC phosphorylation of the third cytoplasmic loop has been shown to disrupt rat CB1 receptor activation of potassium and calcium channels (Garcia et al., 1998) . (c) A conserved lysine in TMDIII is important for receptor interaction with bicyclic but not aminoalkylindole classes of cannabinoid agonists [indicated with a box (Song and Bonner, 1996; Chin et al., 1998) ]. (d) A leucine and alanine pair occurs in the carboxy terminus of the third cytoplasmic loop that has been implicated in G s interaction [indicated with a box (Abadji et al., 1999) ]. (e) Serine residues within the intracellular tail regions correspond to rat CB1 receptor amino acids 426 and 430 (indicated by bold font), which have been implicated in receptor desensitization (Jin et al., 1999) . (f) A potential PKC phosphorylation site occurs within the intracellular tail region of the receptor. The location of these cytoplasmic tail PKC sites (indicated in bold italics) is conserved across species except in the cases of the cat CB1 and the pufferfish CB1B receptors. (g) Amino acids corresponding to rat CB1 receptor residues 460 -463 are required for WIN55212-2-mediated receptor internalization when heterologously expressed in AtT20 cells [indicated with a box ].
Comparison of the predicted amino acid sequence of the nCB1R with cannabinoid receptor sequences available from other species reveals a high degree of conservation (Table 2 ). In the case of human and mouse cannabinoid receptors, where protein sequences for both CB1 and CB2 receptor subtypes are known, this degree of sequence identity is highest within receptor subtype, suggesting that separate CB1 and CB2 receptor subtypes had evolved before divergence of the species.
The nCB1R sequence shares ϳ10% more sequence identity with mammalian proteins than that predicted for the pufferfish CB1A receptor and ϳ20% more than the pufferfish CB1B receptor. Assuming that the pufferfish sequences encode functional receptors, this higher degree of sequence identity suggests that there is less evolutionary distance between mammalian and amphibian CB1 receptors than between mammalian and pufferfish CB1 receptors. This is supported by phylogenetic analyses, and the resulting dendrogram is presented in Fig. 7 . This analysis suggests that evolution of CB1 receptors was an ancient event, which again implies an important functional role.
Our results support the presence of a behaviorally relevant cannabinoid signaling system within the amphibian T. granulosa. This system is regulated by a specific G protein-coupled receptor that, with the exception of its lower affinity for anandamide, is similar in ligand binding specificity, expression levels, primary structure, and signal transduction to that present in other species, including mammals. The high degree of cross-species homology of CB1 receptors indicates that cannabinoid signaling systems have been maintained over the course of vertebrate evolution. This maintenance implies that cannabinoid neurochemistry is of critical functional importance. A clear understanding of the nature of this functional importance is dependent on further cannabinoid research, perhaps using lower vertebrate models such as that described here using T. granulosa. 
